Cite
MLA Citation
Rodney P. Rocconi et al.. “Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL).” Obstetrical & gynecological survey, vol. 76, no. 3, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100142321923.0x000034